{"id":"W4395026193","doi":"10.1016/j.clim.2024.109949","title":"7 Phase 3 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of Patients With WHIM Syndrome: Preliminary Results From Ongoing Open-Label Extension Period of Continuous Mavorixafor Treatment","year":2024,"lang":"en","type":"article","venue":"Clinical Immunology","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Xenon Pharmaceuticals (Canada)","funders":"","keywords":"Open label; Period (music); Medicine; Extension (predicate logic); Antagonist; Internal medicine; Clinical trial; Computer science; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001146241,0.001129085,0.001503377,0.0003536938,0.0004596587,0.001009211,0.0007940914,0.001443247,0.006351314],"category_scores_gemma":[0.0009839995,0.0003535967,0.001768445,0.0002291433,0.0007427513,0.0007079354,0.0002612553,0.003113684,0.00100964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001013299,"about_ca_system_score_gemma":0.001707648,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002479329,"about_ca_topic_score_gemma":0.00698639,"domain_scores_codex":[0.9996241,0.0001707405,0.00001376144,0.00003942036,0.00003938572,0.0001125567],"domain_scores_gemma":[0.9993004,0.0001668789,0.0001011406,0.00004389649,0.00005638706,0.0003313255],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7784634,0.02405108,0.003526222,0.0008406698,0.001572301,0.0004458711,0.0002353072,0.00230742,0.0398737,0.0008520086,0.01341917,0.1344128],"study_design_scores_gemma":[0.7481798,0.232789,0.008132741,0.00007906242,0.0004174373,0.0003416516,0.0000662925,0.001637764,0.003116855,0.000406797,0.004787461,0.00004527763],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807866,0.004780266,0.00127033,0.002613387,0.0004520321,0.002156663,0.002773269,0.0002362056,0.004931229],"genre_scores_gemma":[0.9741114,0.00331658,0.003961984,0.002830325,0.0004490656,0.002511365,0.005325024,0.00005969445,0.007434602],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006351314,"threshold_uncertainty_score":0.02124727,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08793805410892636,"score_gpt":0.4111665087270736,"score_spread":0.3232284546181472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}